Sarah Cannon Research Institute (SCRI) — Denver, Colorado

Sarah Cannon Research Institute (SCRI) is a clinical research site located in Denver, Colorado, United States 80218.

Crixeo Health Trust Score: 66/100 (FAIR). This profile has not yet been claimed by the site owner.

Sarah Cannon Research Institute (SCRI) has participated in 3 clinical trials with 3 currently active.

Therapeutic areas: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC).

Sponsors: Phanes Therapeutics, Regeneron Pharmaceuticals, Quanta Therapeutics.

Sponsor Feasibility Report

Trust Score: 66/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Sarah Cannon Research Institute (SCRI)?

Sarah Cannon Research Institute (SCRI) has a Crixeo Trust Score of 66/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Sarah Cannon Research Institute (SCRI) conducted?

Sarah Cannon Research Institute (SCRI) has 3 clinical trials on record, with 3 currently active. Their work covers Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC).

Is Sarah Cannon Research Institute (SCRI) accredited by Crixeo Health?

Sarah Cannon Research Institute (SCRI) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Sarah Cannon Research Institute (SCRI)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.